The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aimed to validate it in a larger cohort with serum PSA 2.5-10 ng/mL and test other selected transcripts and clinical parameters, including the percentage of free prostate-specific antigen (PSA) (% free PSA) and inflammation. In the main cohort of 299 men, we tested the quadruplex transcripts. In a subset of 146 men, we analyzed additional transcripts (CD45, EPCAM, EZH2, Ki67, PA2G4, PSGR, RHOA and TBP). After a prostate massage, the urine was collected, RNA isolated from a cell sediment and qRT-PCR performed. Ct values of KLK3 (i.e., PSA) were strongly correlated with Ct values of other genes which play a role in CaP (i.e., PCA3, AMACR, TRPM8, MSMB and PSGR). AMACR, PCA3, TRPM8 and EZH2 mRNA expression, as well as % free PSA, were significantly different for BPH and CaP. The best combined model (% free PSA plus PCA3 and AMACR) achieved an AUC of 0.728 in the main cohort. In the subset of patients, the best AUC 0.753 was achieved for the combination of PCA3, % free PSA, EPCAM and PSGR. PCA3 mRNA was increased in patients with inflammation, however, this did not affect the stratification of patients indicated for prostate biopsy. In conclusion, the percentage of free PSA and urinary markers contribute to a more accurate indication for prostate biopsy.

• MeSH
• analýza moči metody   MeSH
• biopsie MeSH
• časná detekce nádoru metody   MeSH
• hyperplazie prostaty MeSH
• lidé MeSH
• nádorové biomarkery * moč   MeSH
• nádory prostaty * diagnóza   MeSH
• prostatický specifický antigen moč   MeSH
• zánět MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

• MeSH
• adhezní molekula epiteliálních buněk metabolismus   MeSH
• dospělí MeSH
• galaktosyltransferasy genetika   MeSH
• kolorektální nádory metabolismus   MeSH
• lidé středního věku MeSH
• lidé MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• sfingolipidy metabolismus   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

Plant hormone brassinosteroids (BRs) have multiple important functions in plants. They have also been found to exhibit anti-tumor, anti-angiogenic and anti-proliferative activity. The experimental part of this article describes the effects of BR biosynthetic precursors on prostate cancer cells. The experiments were performed with LNCaP and DU-145 prostate cancer cell lines. These were cultivated and treated with tested BRs in different concentrations and time intervals. The tested compounds were found to affect cell viability, nuclear receptor expression, cell cycle and apoptosis in the tumor cells. IC50 concentrations were determined based on MTT test and the two most active compounds (cathasterone and 6-oxocampestanol) were used in the next experiments. Cathasterone was the most effective of all tested compounds and effectively inhibited integrity of cell spheres. It was found that both BRs had no significant effect on the cell cycle in LNCaP at IC50 concentration, while in DU-145 a significant block in G0/G1 phase after the BR treatment was observed. The effect of BRs on the nuclear steroid receptors was manifested by changes in their expression and localization. BRs demonstrated their significant effect on prostate cancer cells and the compounds have potential used in anticancer drug research and cancer treatment.

• MeSH
• antitumorózní látky farmakologie   MeSH
• apoptóza účinky léků   MeSH
• brassinosteroidy farmakologie   MeSH
• buněčný cyklus účinky léků   MeSH
• lidé MeSH
• nádorové buněčné linie MeSH
• nádory prostaty farmakoterapie   MeSH
• proteiny regulující apoptózu metabolismus   MeSH
• steroidní receptory metabolismus   MeSH
• viabilita buněk účinky léků   MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

INTRODUCTION: Cytochrome (CYP) epoxygenases (CYP2C and CYP2J) and soluble epoxide hydrolase (sEH) participate in the metabolism of arachidonic acid and may also have a potential role in enterocyte differentiation. The first critical step in the study of intestinal cell differentiation is the determination of a suitable in vitro model, which must be as similar as possible to the conditions of a living organism. It is known that HT-29 and Caco2 cell lines derived from human colorectal carcinomas can differentiate into enterocyte-like cells in appropriate culture conditions. MATERIAL AND METHODS: We tested 4 different approaches of enterocyte-like differentiation and determined the most appropriate culture conditions for each model. Subsequently, the changes in the expression of CYP epoxygenases and sEH in undifferentiated and differentiated cells were measured by In-Cell ELISA. These results were compared with immunohistochemical profiles of expression of CYP epoxygenases and sEH in samples of human embryonic and fetal intestines as well as adult duodenum and colon. RESULTS: Our results show that sodium butyrate (NaBt)-differentiated HT-29 cells and spontaneously differentiated Caco2 cells resemble CYP epoxygenases and sEH profiles, corresponding with different types of intestines. CONCLUSION: Our study revealed that the most suitable models for the study of the role of CYP epoxygenases and sEH expression in differentiation of intestinal epithelium are NaBt-differentiated HT-29 cells and spontaneously differentiated Caco2 cells.

• MeSH
• buněčná diferenciace * MeSH
• buňky HT-29 MeSH
• Caco-2 buňky MeSH
• enterocyty enzymologie   MeSH
• epoxid hydrolasy metabolismus   MeSH
• kyselina arachidonová metabolismus   MeSH
• lidé MeSH
• střeva cytologie   embryologie   MeSH
• střevní sliznice * embryologie   metabolismus   MeSH
• systém (enzymů) cytochromů P-450 metabolismus   MeSH
• techniky in vitro MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

Inhibitors of cyclin-dependent kinases 9 have been developed as potential anticancer drugs for the treatment of multiple myeloma. We have previously prepared a library of arylazo-3,5-diaminopyrazole inhibitors of CDKs. Here, we describe a novel member, AAP1742 (CDK9 inhibition with IC(50) = 0.28 μm), that reduces the viability of multiple myeloma cell lines in low micromolar concentrations. Consistent with inhibition of CDK9, AAP1742 decreases the phosphorylation of RNA polymerase II and inhibits mRNA synthesis of anti-apoptotic proteins Mcl-1, Bcl-2, and XIAP, followed by apoptosis in the RPMI-8226 cell line in a dose- and a time-dependent manner. These results are consistent with the biochemical profile of AAP1742 and further suggest cellular inhibition of CDK9 as a possible target for anticancer drugs.

• MeSH
• aktivace enzymů účinky léků   MeSH
• antitumorózní látky chemie   farmakologie   MeSH
• apoptóza účinky léků   MeSH
• azosloučeniny chemie   farmakologie   MeSH
• cyklin-dependentní kinasa 9 antagonisté a inhibitory   metabolismus   MeSH
• down regulace účinky léků   MeSH
• fosforylace účinky léků   MeSH
• lidé MeSH
• messenger RNA metabolismus   MeSH
• mitochondrie metabolismus   MeSH
• mnohočetný myelom metabolismus   patologie   MeSH
• nádorové buněčné linie MeSH
• protein MCL-1 genetika   metabolismus   MeSH
• protoonkogenní proteiny c-bcl-2 genetika   metabolismus   MeSH
• pyrazoly chemie   farmakologie   MeSH
• RNA-polymerasa II metabolismus   MeSH
• X-vázaný inhibitor apoptózy genetika   metabolismus   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH